BRIEF-Merck sees accelerating declines for Remicade, due to biosimilars By: Reuters: Company News February 03, 2016 at 09:14 AM EST * Says it expects global Januvia/Janumet sales to rise in 2016, when excluding negative impact of strong dollar Read More >> Related Stocks: Eli Lilly Merck & Co